MHRA Drug Safety Update October 2020

MHRA Drug Safety Update October 2020

October 23, 2020

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 14 Issue 2 September 2020) has been published and includes articles on:

  • 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
  • Flucytosine (Ancotil): new contraindication in patients with DPD deficiency
  • Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
  • Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
  • Warfarin and other anticoagulants: monitoring of patients during the COVID19 pandemic
  • Every report counts: report suspected adverse drug reactions and take part in #MedSafetyWeek (2–8 November 2020)
  • Letters and drug alerts sent to healthcare professionals in September 2020 

To see the latest MHRA Drug Safety Updates in full, visit the website

Posted in: , ,

More Latest News >